First US Presentation of DETECT Data Demonstrates Semi-Quantitative Assessment of Endometriosis Lesions Using ⁹⁹ᵐTc-Maraciclatid

Poster presented at SNMMI 2026 shows standardised uptake metrics align with lesion type and expected levels of angiogenesis, including for superficial peritoneal disease.

Serac Healthcare Limited announces the presentation of a poster at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting reporting semi-quantitative imaging data from the DETECT Phase 2 study of ^99mTc-maraciclatide in endometriosis.